Jin Zhang M.D., Ph.D

Jin Zhang M.D., Ph.D is editor at The Pharmaceutical Consultant.

Articles

Bispecific Antibodies in China

Jin Zhang provides an overview of China's major bispecific antibody developers.

The TKI Lung Cancer Market in China

Tyrosine-kinase inhibitors (TKIs) are gradually becoming the most popular option for lung cancer treatment in China. Jin Zhang reports.